Clinical Scorecard: Post-Translational Modifications in Retinoblastoma: Mechanisms, Immune Modulation, and Potential Therapeutic Avenues

At a Glance

Key Highlights

• Retinoblastoma primarily results from RB1 mutations leading to oncogenic characteristics.
• Post-translational modifications (PTMs) significantly influence RB pathway functionality.
• Emerging treatment avenues include targeting PTM enzymes and combining with immunotherapy.
• Survival rates vary significantly between high-income and low-income countries.
• Ongoing surveillance for secondary cancers is crucial for hereditary survivors.

Guideline-Based Recommendations

Diagnosis

• Diagnosis is based on clinical presentation and genetic testing for RB1 mutations.

Management

• Treatment options include focal therapies, systemic chemotherapy, and eye-directed chemotherapy; radiotherapy is minimized.

Monitoring & Follow-up

• Regular follow-up for secondary malignancies, especially in hereditary cases.

Risks

• Increased risk of secondary malignancies following radiation therapy.

Patient & Prescribing Data

Children diagnosed with retinoblastoma, particularly those with hereditary forms.

Focus on preserving vision and globe while ensuring survival; emerging therapies targeting PTMs are under investigation.

Clinical Best Practices

• Utilize genetic counseling for families with hereditary retinoblastoma.
• Implement a multidisciplinary approach for treatment planning.
• Monitor for treatment-related complications and secondary cancers.

Related Resources & Content

• Post-Translational Modifications in Retinoblastoma